There were 112 responses from providers in the United States and Canada.  Most providers were physicians and represented multiple disciplines including neurology, neuro-oncology, medical oncology, neurosurgery, and radiation oncology.  Sixty-four (57%) described themselves as neuro-oncology focused.  Eighty-eight (79%) reported access to neuro-oncology tumor boards.  Sixty-eight (73%)  stated they had access to molecular tumor boards.  Most respondents felt that they were adequately supported to manage neuro-oncology patients.  When dividing responses based on a neuro-oncology focused practice compared to a less neuro-oncology focused practice, there were significant differences between access to molecular tumors boards (85% vs 63%, p=0.023) and access to clinical trials (98% vs 82%, p=0.022). 

This qualitative and quantitative hypothesis-generating data is the start to understanding the challenges faced by community neuro-oncology providers.  These results will guide future studies and recommendations aimed toward better supporting them and their patients.